The C677T variant is a common change in the MTHFR gene that swaps a single building block in the DNA, producing an enzyme that works less efficiently at processing folate. People who carry two copies of this variant (the TT genotype) have meaningfully higher levels of homocysteine in their blood, an amino acid linked to cardiovascular and pregnancy-related risks, especially when their folate intake is low. The variant is remarkably widespread, found in every human population studied, and its health effects range from modest to clinically relevant depending on genotype, diet, and other risk factors.
What C677T Actually Does to the Enzyme
MTHFR stands for methylenetetrahydrofolate reductase, an enzyme that sits at a critical fork in folate metabolism. It converts one form of folate into 5-methyltetrahydrofolate, which the body uses to recycle homocysteine back into methionine. Methionine, in turn, feeds into processes like DNA methylation and protein building. The C677T variant changes a single amino acid in the enzyme from alanine to valine, which makes the resulting protein less stable, particularly at higher temperatures.1PubMed. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity This “thermolabile” version of the enzyme loses its grip on its helper molecule, a derivative of riboflavin (vitamin B2), more easily than the normal version does.2PubMed. The thermolabile variant 677C–>T can further reduce activity when expressed in cis with severe mutations for human methylenetetrahydrofolate reductase
The practical consequence is that people with two copies of the variant (TT genotype) produce less 5-methyltetrahydrofolate. That means less of the methyl-donor form of folate is available for recycling homocysteine, so homocysteine accumulates in the blood. In a large U.S. study, individuals with the TT genotype had homocysteine levels roughly 2.2 micromoles per liter higher and serum folate about 1.4 nanograms per milliliter lower on average than those with the normal CC genotype.3The American Journal of Clinical Nutrition. Prospective study of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of all-cause and cardiovascular disease mortality among 6000 US adults People with one copy of the variant (CT, or heterozygous) tend to fall somewhere in between.
How Common Is the C677T Variant
Unlike many well-known genetic variants that cluster in specific ethnic groups, C677T is found across the globe. A landmark study cataloging its worldwide distribution reported that its frequency is lowest in African populations, at around 7%, and substantially higher in European, Asian, and especially some indigenous American populations.4American Journal of Human Genetics. Worldwide Distribution of a Common Methylenetetrahydrofolate Reductase Mutation One Brazilian indigenous group, for instance, had a T-allele frequency near 45%. In U.S. primary care populations, Hispanic Americans carry the variant at notably higher rates than other groups, while African Americans appear to be relatively protected from MTHFR-related deficiency.5PubMed Central. Ethnogeographic prevalence and implications of the 677C>T and 1298A>C MTHFR polymorphisms in US primary care populations
This wide distribution has puzzled researchers. Evolutionary analysis suggests that the T allele may have been positively selected for in certain environments, possibly because it confers a survival advantage during early embryonic development.6PubMed Central. Human genetic selection on the MTHFR 677C>T polymorphism The variant also shifts folate distribution slightly toward the DNA-synthesis pathway and away from the methylation pathway, which could be beneficial in some dietary and environmental contexts. Whatever the reason, C677T is far too common to be treated as a straightforward “disease mutation.”
Homocysteine and Cardiovascular Risk
The most studied health consequence of C677T is its effect on homocysteine and, by extension, cardiovascular disease. Elevated homocysteine has been associated with damage to blood vessel walls and a higher risk of clotting, stroke, and heart disease. But the relationship between the variant and actual cardiovascular events turns out to be more nuanced than early research suggested.
A large prospective study of over 156,000 Chinese adults, a population where folate fortification of food is not mandatory, found that TT genotype carriers had about a 13% higher risk of stroke overall, with the strongest link to hemorrhagic stroke, where risk was roughly 24% higher. However, the same study found no meaningful association between C677T and heart attack after adjusting for multiple comparisons.7International Journal of Epidemiology. MTHFR and risk of stroke and heart disease in a low-folate population: a prospective study of 156 000 Chinese adults A European study without mandatory folic acid fortification did find a roughly 38% increased risk of ischemic heart disease in TT carriers.8PubMed. MTHFR C677T genotype and cardiovascular risk in a general population without mandatory folic acid fortification These seemingly conflicting results hint at the importance of population context, especially folate intake. Where food is routinely fortified with folic acid, as in the United States and Canada, the gap in homocysteine levels between genotypes shrinks, and so does the apparent cardiovascular risk.
Pregnancy, Neural Tube Defects, and Recurrent Loss
Pregnancy is where C677T attracts the most clinical attention, because the developing fetus has an enormous need for folate during the rapid cell division of the first trimester. If a mother’s folate status is compromised, and the C677T variant makes that more likely, the consequences can be serious.
A meta-analysis pooling 25 case-control studies found that mothers with the TT genotype had roughly double the risk of having a child with a neural tube defect compared to CC mothers.9PubMed Central. Association of the Maternal MTHFR C677T Polymorphism with Susceptibility to Neural Tube Defects in Offsprings: Evidence from 25 Case-Control Studies This finding was consistent across Asian, Caucasian, and mixed-ethnicity populations. A study in Pakistani mothers confirmed the pattern, with the T allele significantly more common among mothers of children with neural tube defects.10PubMed. Low maternal folate concentrations and maternal MTHFR C677T polymorphism are associated with an increased risk for neural tube defects in offspring
The variant has also been linked to recurrent pregnancy loss. A meta-analysis found that mothers homozygous for the C677T variant had about 2.3 times the odds of experiencing recurrent miscarriages compared to those with the CC genotype.11PubMed. Association between maternal, fetal and paternal MTHFR gene C677T and A1298C polymorphisms and risk of recurrent pregnancy loss: a comprehensive evaluation A smaller clinical study found significantly higher rates of the heterozygous CT genotype among women with unexplained recurrent pregnancy loss compared to controls.12International Journal of Reproduction, Contraception, Obstetrics and Gynecology. Association of methylene tetrahydrofolate reductase gene mutation in unexplained recurrent pregnancy loss The relationship with preeclampsia is less clear. A study in Tunisian women found that while TT carriers had a higher ratio of certain angiogenic markers, the overall allele frequency difference between preeclampsia cases and controls did not reach significance after statistical adjustment.13PubMed. Association of MTHFR C677T and A1298C variants with preeclampsia risk and angiogenic imbalance in Tunisian women
Depression and Migraine With Aura
Because folate metabolism feeds into the production of neurotransmitters like serotonin and dopamine, researchers have long suspected that C677T could influence mental health. The evidence for a link to depression is now fairly consistent. A meta-analysis of 26 studies found that people with the TT genotype had about 42% higher odds of depression compared to those with the CC genotype, with a stronger effect observed in Asian populations.14PubMed. Association between MTHFR C677T polymorphism and depression: An updated meta-analysis of 26 studies A later and larger meta-analysis extended these findings across multiple models of comparison, consistently showing elevated depression risk in T-allele carriers.15PubMed Central. Association between variants of MTHFR genes and psychiatric disorders: A meta-analysis One notable wrinkle: the association was not found in elderly populations, possibly because people who are genetically susceptible to depression have already been identified and treated by that age, or because other age-related factors overwhelm the genetic effect.
The variant has also been tied to migraine with aura, a subtype of migraine that includes visual disturbances or sensory symptoms before the headache. An Australian case-control study found that the TT genotype roughly doubled the risk of migraine with aura, with no increased risk for migraine without aura.16PubMed Central. The methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura A follow-up analysis confirmed this association and found that TT homozygotes were also more likely to experience one-sided headache pain.17PubMed Central. Analysis of the MTHFR C677T variant with migraine phenotypes The mechanism likely involves elevated homocysteine damaging small blood vessels in the brain, although the full pathway is still being worked out.
Folate, Riboflavin, and Managing the Variant
The single most actionable thing about the C677T variant is that its health effects depend heavily on B-vitamin status. The enzyme that C677T impairs relies on two vitamins to do its job: folate (B9) as the substrate it acts on, and riboflavin (B2) as its cofactor. When both are abundant, even a less efficient enzyme can keep homocysteine in check. When either is low, the enzyme’s weakness matters much more.
Folate supplementation is the most widely discussed intervention. A randomized trial compared standard folic acid to 5-methyltetrahydrofolate (often sold as “methylfolate” or “5-MTHF”), the already-converted form of folate that bypasses the MTHFR step. Both forms lowered homocysteine significantly, but the methylfolate group saw a roughly 15% reduction compared to about 9% in the standard folic acid group.18The American Journal of Clinical Nutrition. Comparison of the effect of low-dose supplementation with l-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study After supplementation, blood folate levels were similar between the two groups, suggesting that even with a sluggish MTHFR enzyme, most people can still convert standard folic acid adequately, although methylfolate may provide a slight edge.
Riboflavin gets less attention but may be equally important for TT homozygotes. In a clinical study, riboflavin supplementation lowered homocysteine by as much as 22% overall in TT individuals, and by a striking 40% in those who had the poorest riboflavin status at baseline. People with the CC and CT genotypes showed no comparable homocysteine response to riboflavin.19PubMed. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C->T polymorphism This makes sense mechanistically: the variant enzyme loses its riboflavin-derived cofactor more readily, so flooding the system with extra riboflavin helps stabilize it. The interaction between folate and riboflavin was explored in a separate study, which confirmed that both vitamins work together to lower homocysteine, with lower riboflavin status independently associated with higher homocysteine regardless of genotype.20Clinical Chemistry. Effect of Riboflavin Status on the Homocysteine-lowering Effect of Folate in Relation to the MTHFR (C677T) Genotype
The A1298C Variant and Compound Carriers
C677T is not the only common variant in the MTHFR gene. A second variant, A1298C, changes a different amino acid and also reduces enzyme activity, though generally to a lesser degree than C677T. Things get more interesting when someone carries one copy of each variant on different chromosomes, a situation called compound heterozygosity. Roughly 2% to 3% of the general population falls into this category.21Ewha Medical Journal. Compound heterozygosity with methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C mutations likely causing recurrent thrombotic events in a middle-aged man: a case report
Whether compound heterozygosity significantly raises homocysteine is debated. One study measuring homocysteine in individuals heterozygous for both variants found that the differences in fasting homocysteine did not reach statistical significance compared to those without either variant.22Clinical Chemistry. C677T and A1298C Polymorphisms of the Methylenetetrahydrofolate Reductase Gene: Incidence and Effect of Combined Genotypes on Plasma Fasting and Post-Methionine Load Homocysteine in Vascular Disease However, case reports have linked compound heterozygosity to recurrent blood clots, particularly in people who also have other risk factors such as oral contraceptive use or pregnancy. A study in South Indian patients with deep vein thrombosis found roughly a 3.5-fold higher risk among compound heterozygotes, though this came from a relatively small sample and a specific population.
The meta-analysis on recurrent pregnancy loss also found that A1298C contributed independently: fetal carriers of at least one 1298C allele had about 1.5 times the odds of recurrent pregnancy loss, even when the C677T variant was considered separately.11PubMed. Association between maternal, fetal and paternal MTHFR gene C677T and A1298C polymorphisms and risk of recurrent pregnancy loss: a comprehensive evaluation So while A1298C alone is generally considered less impactful than C677T, its combination with C677T may matter in certain clinical situations.
Why Most Medical Guidelines Recommend Against Routine Testing
Given all these associations, you might expect MTHFR testing to be standard practice. It is not. The American College of Medical Genetics and Genomics (ACMG) explicitly advised against routine MTHFR polymorphism testing, a position it has reaffirmed.23PubMed. Addendum: ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing Their reasoning is straightforward: the clinical evidence does not show that knowing someone’s MTHFR genotype changes their treatment. Homocysteine can be measured directly if there is a reason to check it, and the recommended treatment for high homocysteine (B-vitamin supplementation and adequate folate intake) is the same regardless of genotype.
This is a source of frustration for people who have had MTHFR testing done through direct-to-consumer genetic services or integrative medicine practitioners. The wellness space has built an elaborate narrative around MTHFR variants, often suggesting that carriers need specialized “methylated” supplements, should avoid folic acid entirely, and may need to follow highly specific protocols. The scientific literature does not support most of these claims at the level they are made. Standard folic acid is converted to active folate through multiple enzymatic steps, and even TT homozygotes can process it, as the supplementation trial data show. Whether methylfolate has a meaningful clinical advantage over folic acid in real-world health outcomes, as opposed to a modest additional drop in homocysteine, has not been established in large trials.
Methotrexate and Drug Interactions
One area where C677T genotype does appear to make a practical difference is in how people tolerate certain medications, particularly methotrexate. Methotrexate works partly by interfering with folate metabolism, which is how it kills rapidly dividing cancer cells and dampens overactive immune responses. If your MTHFR enzyme is already running at reduced capacity, adding a drug that further disrupts folate pathways can tip the balance toward toxicity.
In osteosarcoma patients receiving high-dose methotrexate, those with the CT or TT genotype showed higher rates of liver toxicity and fever reactions compared to patients with the normal CC genotype, even though there was no difference in tumor response or survival between groups.24PubMed Central. More severe toxicity of genetic polymorphisms on MTHFR activity in osteosarcoma patients treated with high-dose methotrexate A study of pediatric patients on high-dose methotrexate similarly found that carriers of the T allele had about 1.7 times the risk of liver impairment and 1.5 times the risk of mucosal damage compared to CC patients.25PubMed Central. Relationship between methylenetetrahydrofolate reductase gene polymorphisms and methotrexate drug metabolism and toxicity These findings are consistent enough that oncologists and rheumatologists increasingly consider MTHFR status when managing methotrexate side effects, even if routine testing for the general population is not recommended.
Effects on DNA Methylation
Because the MTHFR enzyme ultimately supplies methyl groups used to silence or activate genes through DNA methylation, there has been substantial interest in whether the C677T variant alters methylation patterns throughout the genome. The picture here is inconsistent. A study looking at global DNA methylation in oral cells found no significant differences between CC, CT, and TT carriers.26PubMed Central. The MTHFR C677T polymorphism and global DNA methylation in oral epithelial cells But a more targeted analysis found that TT individuals did show increased methylation at specific genomic regions, including the MTHFR gene’s own regulatory area, and that riboflavin supplementation altered these methylation patterns.27PubMed. Riboflavin supplementation alters global and gene-specific DNA methylation in adults with the MTHFR 677 TT genotype
This disconnect between global and gene-specific methylation results is typical of epigenetics research at this stage. Global methylation is a blunt measurement that may not capture subtle, localized changes. The fact that riboflavin supplementation could shift methylation patterns in TT carriers opens up an interesting question about whether B-vitamin intake might influence gene regulation in these individuals over the long term, but researchers are still far from translating these observations into clinical recommendations.
Colorectal Cancer and the Folate Paradox
The C677T story takes an unexpected turn when it comes to certain cancers. Because the variant reduces the enzyme’s activity and shifts folate distribution slightly toward the DNA-synthesis arm of the pathway (and away from methylation), it might actually protect against some cancers where DNA stability is the bottleneck. The most studied example is colorectal cancer.
A systematic review and meta-analysis found that both CC and TT genotype individuals benefited from higher folate intake in terms of colorectal cancer risk. Among those with the CC genotype, high versus low folate intake was associated with about a 30% reduction in risk, and among TT carriers, the reduction was roughly 37%.28PubMed Central. Folate Intake, MTHFR Polymorphisms, and the Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis Some earlier observational studies had even suggested that TT homozygotes might have a slightly lower baseline colorectal cancer risk than CC carriers, potentially because the shift in folate toward DNA synthesis reduces the chance of dangerous mutations accumulating during rapid cell division in the gut lining. This “folate paradox” is a reminder that a genetic variant is not simply “good” or “bad” in isolation. Its effects depend on the tissue, the disease, and the nutritional environment.
The interplay between C677T and cancer risk remains an active area of research, and the findings are not uniform across all cancer types. For colorectal cancer specifically, the takeaway is that maintaining good folate status is beneficial regardless of genotype, and that the C677T variant may modestly enhance rather than undermine the protective effect of folate intake in this particular context.